Viatris reported $14.7B of revenue over the trailing twelve months, +4.4% on the year before. 7 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $14.7B (to Q2 2026). Free cash flow: $1.95B, trailing twelve months to Q2 2026. Operating margin: −0.64%, trailing twelve months to Q2 2026. EPS: −$0.36, trailing twelve months to Q2 2026.

VTRSViatris

Healthcare

$17.66+84% 1Y

$17.66

$9.2352 weeks$18.27

VTRS as reported

Viatris reported $14.7B of revenue over the trailing twelve months, +4.4% on the year before. 7 reported series are charted on this page, each one as filed.

$14.7B

Revenue, trailing twelve months · to Q2 2026 · +4.4% against the twelve months before

Free cash flow: $1.95B
Free cash flow · +12% year on year · trailing twelve months to Q2 2026
Operating margin: −0.64%
Operating margin · trailing twelve months to Q2 2026
EPS: −$0.36
EPS · −88% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for VTRS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$14.7B	+4.4%	Q2 2026
EPS	−$0.36	−88%	Q2 2026
Gross margin	35%	n/a	Q2 2026
Operating margin	−0.64%	n/a	Q2 2026
ROIC	−3.7%	n/a	Q2 2026
Free cash flow	$1.95B	+12%	Q2 2026
P/E	52.9	n/a	Q4 2023 · 10 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.